XENOTRANSPLANT FOR CNS THERAPY
First Claim
1. An implant, for implantation into the brain of a recipient mammal, having Huntington'"'"'s chorea, said implant comprising a population of living non-human choroid epithelial cells that are encapsulated within a biocompatible capsule, the wall of said capsule at least partially composed of a semi-permeable membrane, wherein said membrane admits metabolites for sustaining said cells and permits a therapeutically-effective amount of one or more factors selected from the group consisting of IGF, TGF-a, RA, NGF, VEG and FGF to exit from said implant into said brain.
0 Assignments
0 Petitions
Accused Products
Abstract
A “supplementary choroid plexus” comprising preferably a xenotransplant of choroid plexus cells from a neonatal mammal provides a steady supply of trophic factors for administration to a central nervous system in need of treatment for a neurological disease. Choroid plexus cells manufacture a range of trophic factors, particularly during fetal development. This neurotrophic factor therapy may be useful in treating clinical and subclinical neurodegenerative diseases particularly those in which the choroid plexus has often become atrophic. The xenotransplant is cloaked in a protective layer (such as of alginate) capable of concealing the foreign nature of the transplant. Lateral ventricles are the preferred implantation site, from where the trophic factors are carried through the neuropil by the circulation of cerebrospinal fluid.
33 Citations
31 Claims
- 1. An implant, for implantation into the brain of a recipient mammal, having Huntington'"'"'s chorea, said implant comprising a population of living non-human choroid epithelial cells that are encapsulated within a biocompatible capsule, the wall of said capsule at least partially composed of a semi-permeable membrane, wherein said membrane admits metabolites for sustaining said cells and permits a therapeutically-effective amount of one or more factors selected from the group consisting of IGF, TGF-a, RA, NGF, VEG and FGF to exit from said implant into said brain.
-
2-14. -14. (canceled)
-
29. An implant, for implantation into the brain of a recipient human having Huntington'"'"'s chorea, said implant comprising a population of living porcine choroid epithelial cells encapsulated within a biocompatible capsule that comprises alginate, wherein the wall of said biocompatible capsule comprises a semi-permeable membrane that admits metabolites for sustaining said cells, blocks access to said implant by factors of the immune system of said recipient human, and permits a therapeutically-effective amount of one or more factors selected from the group consisting of IGF, TGF-α
- , RA, NGF, VEG and FGF to exit from said implant into said brain for a time sufficient to treat Huntington'"'"'s chorea.
-
30. An implant, for implantation into the brain of a recipient human having Huntington'"'"'s chorea, said implant comprising a population of living porcine choroid epithelial cells that are encapsulated within a biocompatible capsule, comprising alginate, wherein the wall of said capsule at least partially comprises a semi-permeable membrane that admits metabolites for sustaining said cells, blocks access to said implant by factors of the immune system of said recipient human, and permits a therapeutically-effective amount of one or more factors selected from the group consisting of IGF, TGF-α
- , RA, NGF, VEG and FGF to exit from said implant into said ventricle for a time sufficient to treat said Huntington'"'"'s chorea.
Specification